Publication Name	World Journal of Hepatology
Manuscript ID	86248
Country	China

Received	2023-06-08 03:54
Peer-Review Started	2023-06-08 03:55
To Make the First Decision
Return for Revision	2023-08-07 02:50
Revised	2023-08-21 02:26
Second Decision	2023-09-14 02:53
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-09-14 08:57
Articles in Press	2023-09-14 08:57
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-09-19 07:37
Publish the Manuscript Online	2023-09-22 12:27

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet
Manuscript Source	Unsolicited Manuscript
All Author List	Yun-Kai Dai, Hai-Na Fan, Kai Huang, Xin Sun, Zhi-Min Zhao and Cheng-Hai Liu
Funding Agency and Grant Number	Funding Agency Grant Number National Science and Technology Major Project No. 2014ZX10005001 and No.2018ZX10302204 National Natural Science Foundation of China No. 81730109 and No. 82274305 Shanghai Key Specialty of Traditional Chinese Clinical Medicine No. shslczdzk01201 China Postdoctoral Science Foundation No. 2022M722162 Siming Youth Fund of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine No. SGKJ-202104
Corresponding Author	Cheng-Hai Liu, MD, PhD, Director, Director, Doctor, Doctor, Professor, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and Shanghai Key Laboratory of Traditional Chinese Clinical Medicine and Key Laboratory of Liver and Kidney Diseases, Institute of Liver Diseases, No. 528 Zhangheng Road, Pudong New Area, Shanghai 201203, China. chenghai.liu@shutcm.edu.cn
Key Words	Serum metabolomics; Differential metabolites; Therapeutic responders; entecavir; FuzhengHuayu tablet; Hepatitis B virus-related liver fibrosis
Core Tip	This study will use high-performance liquid chromatography-tandem mass spectrometry and multivariate statistical modelings to predict serum metabolites of the treatment (entecavir or entecavir + FuzhengHuayu tablet) that effectively reversed hepatitis B virus-related liver fibrosis. It is of great theoretical and practical significance to prevent the transformation of liver fibrosis to cirrhosis or even hepatocellular carcinoma and reduce the social burden.
Publish Date	2023-09-22 12:27
Citation	Dai YK, Fan HN, Huang K, Sun X, Zhao ZM, Liu CH. Baseline metabolites could predict responders with hepatitis B virusrelated liver fibrosis for entecavir or combined with FuzhengHuayu tablet. World J Hepatol 2023; 15(9): 1043-1059
URL	https://www.wjgnet.com/1948-5182/full/v15/i9/1043.htm
DOI	https://dx.doi.org/10.4254/wjh.v15.i9.1043

Full Article (PDF)	WJH-15-1043-with-cover.pdf
Full Article (Word)	WJH-15-1043.docx
Manuscript File	86248_Auto_Edited-JLW.docx
Answering Reviewers	86248-Answering reviewers.pdf
Audio Core Tip	86248-Audio core tip.m4a
Biostatistics Review Certificate	86248-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	86248-Conflict-of-interest statement.pdf
Copyright License Agreement	86248-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	86248-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s)	86248-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	86248-Institutional review board statement.PDF
Non-Native Speakers of English Editing Certificate	86248-Language certificate.pdf
Supplementary Material	86248-Supplementary material.pdf
Peer-review Report	86248-Peer-review(s).pdf
Scientific Misconduct Check	86248-Bing-Qu XL-2.png
Scientific Editor Work List	86248-Scientific editor work list.pdf
CrossCheck Report	86248-CrossCheck report.pdf